Ascella Biosystems, Inc., the parent company of Ascella Bio JAPAN, Inc., has been awarded a grant under the Rapid Acceleration of Diagnostics (RADx) program of the U.S. National Institutes of Health (NIH).
The grant supports research and development of AscellaOne, the molecular diagnostic platform we are developing, including assay design for respiratory pathogens and freeze-dried reagent technology. Ascella Bio JAPAN works with its parent company on this research and development.
AscellaOne is an investigational platform. It has not been cleared, approved or authorized by the U.S. Food and Drug Administration or any other regulatory authority, and it is not available for sale in any country.